Outpace Bio develops engineered T cell therapies using AI-powered protein design to program immune cells for improved function inside patients with solid tumors. The company is advancing an internal pipeline of programmed T cell product candidates, led by CEO and co-founder Marc Lajoie, PhD. Its lead program, OPB-101, is a mesothelin-specific CAR T cell enhanced by Outpace’s OUTSMART™, OUTLAST™, OUTSPACER™, and OUTSAFE™ technologies. OPB-101 is on track for IND clearance and first dosing in 2025 for patients with advanced platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Proceeds from the recent financing will be used to advance multiple candidates to early clinical proof-of-concept and to expand the company’s plug-and-play technology platform for future programs. The company is based in Seattle, WA. Outpace Bio is developing a platform to create next-generation smart cell therapies by applying protein design and synthetic biology. The company combines the design of improved biological functions with cellular control modalities to harness cellular biology's complexity and improve safety and efficacy of cell and gene therapies. Founded by Lyell co-founders Marc Lajoie and Scott Boyken and a scientific team spun out of Lyell Immunopharma, the team has spent the past two years addressing challenges facing anticancer T cell therapies. Outpace is expanding beyond T cells to bring its technology across the broader cell and gene therapy field. The company closed a $30m Series A financing and intends to use the funds to demonstrate proof of principle for its platform. It also entered a collaboration with Lyell Immunopharma for joint research and potential development and commercialization of an immune cell therapy for cancer.

Total raised

$174M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2024